Roche’s Second Actemra Pivotal Trial Supports Novel IL-6 Inhibitor In Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche expects two additional Phase III clinical trials evaluating tocilizumab to report later this year.